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Introduction
Respiratory drug delivery is currently considered to be 
the most promising method for directly relieving or 
treating respiratory diseases such as asthma. As 
compared with other methods, there are some unique 
advantages to this type of respiratory drug administration 
such as quick onset of action and avoided degradation of 
drug by liver. However, one of the drawbacks attributed 
to pulmonary drug delivery is considerable deposition of 
drug particles in undesired locations, which reduces its 
effectiveness and unfavorable take-up of medication 
poses health hazards to patients.1,2 Optimum aerosol 
particle size is very important for deep lung delivery and 
is in the range of 1‐5 µm. Small particles will be exhaled 
and large particles deposited on the oropharynx and 
larynx. Among all pulmonary devices, metered-dose 
inhalers (MDIs) are undoubtedly the most popular and 
commonly used devices for pulmonary drug delivery. 
However, it has been reported that they show low 
efficacy and only as little as 9 % of the delivered doses 
are deposited in the lungs.3,4 It was claimed that to 
improve the depth of penetration of medication to the 
lungs, the esophageal impaction and consequently 
swallowing of the pharmacologic agent should be 
minimized. For this purpose, the special devices were 
employed to reduce undesirably high initial momentum 
which finally decreases the size of primary emitted 
droplets and unwanted deposition of particles in the oral 
cavity and upper airways.1,5 Therefore, it is becoming 
more and more routine to use some sort of extension, 
namely respiratory spacers which sometimes called 
holding chambers, between inhaler outlet and mouth 
inlet.6,7 Various spacers with different shapes and 
volumes were commercially marketed and employed. 
The aim of this study was to compare the effect of two 
widely distributed spacer devices pear type and roller 
type on the in vitro performance of a commercial 
Beclomethasone Dipropionate (BDP) MDI. 
 
Materials and Methods 
Materials 
Beclomethasone Dipropionate (BDP) anhydrous was 
provided from Cipla chemical Company (Mumbai, 
India). HPLC grade acetonitrile was purchased from 
Duksan Pure Chemicals (Kyungkido, Korea). Ethanol 
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Abstract 
Purpose: Respiratory drug delivery has been attracted great interest for the past decades, 
because of the high incidence of pulmonary diseases. However, despite its invaluable 
benefits, there are some major drawbacks in respiratory drug delivery, mainly due to the 
relatively high drug deposition in undesirable regions. One way to improve the efficiency of 
respiratory drug delivery through metered-dose inhalers (MDI) is placing a respiratory 
spacer between the inhaler exit and the mouth. The aim of this study was to assess the effect 
of type and shape of spacer on the aerosolization performance of MDIs.  
Methods: A commercial Beclomethasone Dipropionate (BDP) MDI alone or equipped with 
two different spacer devices (roller and pear type) widely distributed in the world 
pharmaceutical market was used. The effect of spacers was evaluated by calculating 
aerosolization indexes such as fine particle fraction (FPF), mass median aerodynamic 
diameters (MMAD) and geometric standard deviation (GSD) using the next generation 
impactor. 
Results: Although one of the spacers resulted in superior outcomes than the other one, but it 
was not statistically significant. 
Conclusion: The results confirmed that the type and shape of spacer did not substantially 
influence the aerosolization performance of MDIs. 
Short Communication 
*Corresponding author: Hamed Hamishehkar, Tel and Fax: +98 41 33363231, Email: Hamishehkarh@tbzmed.ac.ir 
©
2016 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits 
unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from 
the authors or the publishers. 
 Momeni et al. 
and Tween® 80 were supplied from JATA (Arak, Iran) 
and Merck Chemicals (Darmstadt, Germany) companies, 
respectively. Commercialized BDP MDI (Beclotrox® 
250 µg/dose) was obtained from Jaber Ebne Hayyan 
Pharmaceutical Co. (Tehran, Iran). Roller type spacer 
(Asannafas®) and pear type one (Damyar®) were 
provided from Tehran Fanavar Teb (Tehran, Iran) and 
Fanavar Teb Espadana (Isfahan, Iran) Companies, 
respectively.  
 
Methods 
Characteristics of spacers 
The characteristics of investigated spacers were 
mentioned in Table 1. The only difference is shape of the 
spacers as illustrated in Figure 1, as well.  
 
Table 1. Comparison of spacer’s characteristics. 
Spacer Shape Length(cm) Volume (mL) Expiratory valve 
Damyar
®
 Roller 10.5 130 √ 
Asannafas
®
 Pear 10.5 150 √ 
 
 
 
Figure 1. Pear type spacer (left) and Roller type (right). 
  
In vitro aerosolization assessment  
The aerodynamic particle size distribution of BDP MDI 
with and without spacers was analyzed according to the 
USP monograph using the next generation impactor (NGI) 
(Copley Scientific, Nottingham, UK).8 The induction port 
was used to connect the NGI device to MDI. To ensure an 
efficient particle capture and prevent inter-stage losses due 
to particle bounce, the particle collection surface of each 
stage was coated with Tween® 80. For this purpose, every 
eight collection cups of the NGI were soaked into Tween® 
80 ethanolic solution (1 %) and placed under the fume 
hood until the complete evaporation of ethanol. The cups 
were placed into the apertures in the cup tray and the cup 
tray was located into the bottom frame and lowered into 
place. The impactor lid was closed with the sealed body 
attached and the handle was operated to lock the impactor 
together. The induction port was connected to the first 
stage of the NGI. The flow rate was calibrated using a 
flow meter (DFM 2000, Copley Scientific, Nottingham, 
UK) and fixed at 30 L/min. Once the assembly had been 
checked and found to be airtight, after shaking and one 
actuation to out, a Beclotrox® MDI had been inserted into 
the rubber mouthpiece attached to the USP induction port 
of the NGI. The vacuum pump (HCP5, Copley Scientific, 
Nottingham, UK) was switched on and let it to reach the 
steady flow rate (30 L/min), and finally the dose was 
released for two times in the interval of 5 seconds. The 
pump was switched off after 5 seconds of the second 
actuation. After firing 2 doses into the apparatus, spacer, 
throat and stages were rinsed with 15 mL of acetonitrile: 
water (60: 40, v/v) solution, and the amount of BDP was 
analyzed using a validated HPLC method. Assays were 
repeated six times with or without each spacer and the 
results are presented as averages with standard deviations. 
Fine particle fraction (FPF), mass median aerodynamic 
diameter (MMAD), and geometric standard deviation 
(GSD) indexes were calculated using the Copley Inhaler 
Testing Data Analysis Software (CITDAS, version 3.10). 
The MMAD is defined as the diameter at which 50% of 
the particles by mass are larger and 50% are smaller, 
whereas the FPF corresponds to the fraction of drugs 
carried in particles with a diameter of <5µm.7 
 
High performance liquid chromatography analysis 
The amount of BDP was analyzed using a reversed-phase 
HPLC system employing Knauer apparatus (Germany) 
consisted of a model 1000 HPLC pump and a model 2600 
tunable absorbance detector. BDP was separated at room 
temperature by a C18 column (4.6 mm×250 mm, 10 µm, 
125 A°) (Germany). The mobile phase was consisted of 
acetonitrile and water (60:40). The flow rate was 2 
mL/min and sample injection volume was 20 µL. The 
detecting wavelength was set at 254 nm. The retention 
time was approximately 5 min and the area under the 
curve of BDP peak was calculated by apparatus software 
(ChromGate Client/Server, version 3.1.7) where responses 
were linear in the range of 1–40 µg/mL (r2=0.9981).  
 
Statistical analysis 
Data are expressed as a mean value ± standard deviation 
(SD). Statistical analysis was performed using a one-way 
analysis of variance (ANOVA) with multiple comparisons 
between deposition data using a Tukey-Kramer HSD test 
by SPSS software (version 13.0, Chicago, IL, USA). A P 
value <0.05 was considered statistically signiﬁcant. 
 
Results and Discussion 
The clinical effects of inhaled asthma drugs are 
determined by the total amount of drug deposited in the 
lungs, and its distribution amongst airways with different 
sizes. MDIs have been the traditional means of delivering 
inhaled asthma drugs. For inhaled corticosteroids such as 
BDP, it is recommended that MDIs are used in 
conjunction with a large volume spacer device for the 
delivery of any dose especially in children.9-11 Spacer 
devices reduce the total body dose of inhaled drugs, which 
may result in fewer local and systemic side effects. In 
addition, spacers are able to reduce the problems of co-
ordination that some patients have with MDIs.11,12 In 1997, 
a group of pharmaceutical companies involved in the 
development and manufacturing inhalers formed an 
association to develop a new impactor specifically 
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designed for testing pharmaceutical inhalers using the very 
newest and modern designed theory. In practice, its 
flexibility of use and high productivity are making NGI 
the most popular testing machine within many inhaler 
research laboratories. NGI was launched in 2000 and was 
subsequently accepted into the European Pharmacopeia as 
Apparatus E and into the United States Pharmacopeia as 
Apparatus 5 and 6 in 2005. The in vitro parameters which 
should be measured for each spacer including FPF, 
MMAD and GSD are shown in Table 2. The details of 
BDP deposition in different stages of NGI are presented in 
Figure 2. Although both spacer devices improved all 
aerosolization indexes, only the difference of FPF value 
was statistically significant (Pvalue < 0.01). FPF value 
shows the fraction of BDP particles reach to the lower 
parts of lung. The higher FPF value indicates the better 
aerosolization performance of MDI. The results illustrated 
that the efficacy of BDP MDI increased by 58 and 70 % 
when pear and roller type spacers were used, respectively. 
Although it seems that the increase in FPF value by using 
roller type spacer was higher than pear type but it was not 
statistically significant (Pvalue = 0.412). Ideal MMAD value 
for pulmonary drug delivery is between 1 to 5 µm. All the 
results even without using spacer were in the acceptable 
range. GSD exhibits the aerodynamic size distribution of 
aerosolized particles through the MDIs calculated from 
drug deposition in the various stages of NGI. The lower 
GSD values indicates the narrower size distribution which 
guarantees reproducible and predictable therapeutic 
outcomes. Only roller type spacer improved GSD value of 
BDP MDI (Pvalue = 0.046). Although pear type spacer 
improved GSD value, as well but it was not statistically 
significant (Pvalue = 0.956).  
 
Table 2. In vitro characteristics of Beclomethasone Dipropionate 
delivered from Beclotrex® MDI alone and in combination with 
spacers. Data are presented as mean ± standard deviation. 
Device FPF
a
 (%) MMAD
b
 (µg) GSD
c
 
Beclotrex
®
 42.90±11.18 2.77±0.54 2.55±0.612 
Beclotrex
®
+Asannafas
®
 67.87±10.68 2.64±0.40 2.45±0.32 
Beclotrex
®
+Damyar
®
 72.93±6.33 2.07±0.26 1.93±0.13 
a: Fine Particle Fraction 
b: Mass Median Aerodynamic Diameter 
c: Geometric Standard Deviation 
 
 
Figure 2. Comparison of the amount of Beclomethasone deposited 
in various stages of NGI (Data presented as mean ± SD, n= 3) 
 
The change from oral to inhaled medications as the 
preferred route of administration has been one of the 
most important developments in asthma treatment and 
chronic obstructive pulmonary disease. Unfortunately, 
patients with asthma have been shown to have poor 
inhaler technique which is an important cause of poor 
asthma control. The inhalation method is an important 
variable in the delivery of inhaled drugs. Furthermore, 
although several spacers and holding chambers are 
available, numerous studies showed that healthcare 
devices have poor inhaler technique and dose delivery 
varies considerably depending on the design.3,13,14 The 
most important factors influencing output from MDI plus 
add-on device are: spacer material and volume, dead 
space between inlet and outlet, inlet and outlet valve 
controls, drug formulation, propellants, evaporation rate 
and humidity.11,15,16 Each brand of spacer device has 
different drug delivery characteristics and the impaction 
plane and deposition curves with distinct cut-off sizes 
could be altered. Therefore, the specific design should be 
chosen to guarantee passing favorable particles through 
the spacer.1,17,18 Last but not least, keeping flow 
turbulence down to a minimum is recommended to 
diminish particle deposition which suited to the preferred 
particle size criteria and a sharper cut-off curve. The 
disadvantages of spacers are that they are bulky, and 
difficult to carry out. In addition, the valves sometimes 
stick or become otherwise faulty.7,18 But as shown in the 
present study, the use of spacers for efficient drug 
delivery into the lung and consequently effective 
therapeutic outcome is necessary.  
 
Conclusion 
The esophageal impaction and consequently swallowing 
of the pharmacologic agent which causes side effects in 
oropharynx and gastrointestinal tract is the main 
disadvantages of MDIs that can be prevented by the use 
of a suitable spacer. The results of the present study 
confirmed the importance, beneficial and advantages of 
using spacers with MDIs. The results showed that the 
performance of MDIs could even be improved up to 
70%, however the shape of spacer did not affect the 
aerosolization performance of MDI significantly. Due to 
the great impact of spacer on the outcomes of MDI, 
further investigations on the designing of new spacers or 
exploring the factors affecting the performance of 
spacers such as length, shape, and volume of spacers are 
opened to be discovered.  
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